Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA CONCURS: No confirmation of new GLP-1, DPP-4 pancreatic concerns

This article was originally published in Scrip

Executive Summary

After alerting prescribers and patients in March about the possibility GLP-1-based diabetes therapies, also known as incretin mimetics, increase the risk of pancreatitis and pre-cancerous cellular changes in patients with type 2 diabetes, the FDA joined European regulators in concluding the currently available data do not confirm those concerns.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC022263

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel